Please login to the form below

Not currently logged in
Email:
Password:

Swedish regulator rules Boehringer press release is advertising

German pharma company fails to appeal decision

Boehringer Ingelheim headquarters

The Swedish Medical Products Agency (MPA) has upheld its decision to prevent Boehringer Ingelheim from using a press release about its oral anticoagulant Pradaxa (dabigatran).

The medicines regulator ruled that the press release constituted advertising a prescription-based product to the general public – which is prohibited under Swedish and European law.

The release publicised the company's plans to lower the price for Pradaxa in Sweden and was published on the journalist website mynewsdesk.com in May 2011.

Boehringer Ingelheim Pradaxa dabigatran packMPA's assessment of the press release was that it had addressed the public with positive information about the product and therefore breached Swedish regulations.

Boehringer appealed the MPA's initial September 2011 ruling, but the company's bid has now failed.

In a written comment on the case, legal firm Bird & Bird said: "The Agency […] stated that the text in the press release has clear advertising character which only describes the advantages of the product with no mention of the disadvantages."

However, the firm added: "The 'public' in this case comprised journalists, as the press release was explicitly targeted at journalists."

Throughout its appeal, Boehringer contended the press release should not be construed as advertising, arguing that it "followed old established praxis regarding issuing press releases in Sweden," and that such communications were protected as freedom of speech.

Following the verdict, the president of the Swedish pharmaceutical trade association LIF, Anders Blanck, expressed his disappointment at the decision.

He said the court has "chosen to completely ignore the clear and long-established practice" of providing journalists with press releases.

Blanck added: "We will now analyse the judgement in detail, and may later decide [if] LIF and the company concerned will proceed in the matter."

25th February 2013

From: Marketing, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics